Is there an association between the need for medical puberty induction and the diagnosis or treatment received in girls who have undergone cryopreservation of ovarian tissue for fertility preservation?
Introduction
During the last 30 years, there has been a considerable increase in the survival of childhood cancer as a result of improved antineoplastic treatments. In particular, the use of multiagent chemotherapy has increased the combined 5-year survival rate for childhood cancers in Europe to~70-82% (Edgar et al., 2009; Gatta et al., 2014; The Childhood Cancer Foundation, 2015) . This translates into~300 000 and 500 000 childhood and adolescent cancer survivors in Europe, respectively (Winther et al., 2015) .
One of the major concerns of the increasing number of long-term female childhood cancer survivors is the adverse effect of treatment on their fertility and the chances of becoming pregnant. Chemotherapy and radiation therapy (RT), especially exposure to high doses of alkylating agents and abdominal irradiation, are well-known risk factors that can result in acute ovarian failure, reduced fertility and premature ovarian insufficiency (POI), due to a premature depletion of the follicular pool (Larsen et al., 2003a,b; Wallace et al., 2005a; Green et al., 2009; Wo and Viswanathan 2009; Schmidt et al., 2010 Schmidt et al., , 2013 Crowne et al., 2015; Tonorezos et al., 2015) . Another well-documented risk is that long-term childhood cancer survivors, although still menstruating, have an increased risk of developing POI before the age of 40 years (Sklar et al., 2006) . POI not only renders these patients infertile, but it is also associated with an increased risk of cardiovascular mortality and osteoporosis (Shuster et al., 2010) .
Even though the ovarian reserve is higher in young girls and they tolerate a higher gonadotoxic insult than older patients, it is difficult to identify which patients are at risk of developing POI later in life. The ovarian pool of follicles decreases dramatically in the young years and adolescents may have an approximately two to three times higher risk of POI than younger girls when treated with radiotherapy (Anderson et al., 2015) . In addition, treatment protocols rapidly change and the scheduled treatment plan may be altered depending on the patient's response to treatment. For example, an initial mild treatment with a low risk of gonadotoxicity can be followed by a regimen with a high risk of gonadotoxicity.
The only available option for these young girls to preserve fertility is limited to ovarian tissue cryopreservation (OTC) (Schmidt et al., 2010) . Fertility preservation is also of importance to girls with other conditions such as Turner syndrome or galactosaemia, which can cause premature depletion of ovarian follicles, or non-malignant diseases, that require haematopoietic stem cell transplantation (SCT).
Over the last 15 years, OTC has become an established technique in many countries. However, there is still limited knowledge of how patients respond to transplanted tissue collected prior to puberty. Poirot et al. (2012) published a case of a girl who at the age of 10 had OTC performed and at the age of 13 had her puberty induced by transplanting ovarian tissue. In 2013, a successful puberty induction was reported in Denmark in a 13-year-old girl who had ovarian tissue excised at the age of 9 years due to Ewing's Sarcoma (Ernst et al., 2013a) . Recently, a 27-year-old woman, who had tissue frozen when she was 14 years of age, became pregnant after transplantation and gave birth to a baby (Demeestere et al., 2015) .
Information on girls younger than 18 years of age who undergo OTC is still limited with only a few publications, each describing a relatively small series of patients (Poirot et al., 2002; Feigin et al., 2007; Poirot et al., 2007; Anderson et al., 2008; Borgström et al., 2009; Oktay and Oktem, 2009; Revel et al., 2009; Jadoul et al., 2010; Schmidt et al., 2013; Wallace et al., 2014) . These different studies all concluded that there is no reason to doubt the efficacy and safety of the procedure for these young patients. Only one study has been published on the follow-up of a cohort of young female patients under the age of 18 years (Wallace et al., 2014) .
The aim of our study was to describe a cohort of 176 young Danish girls and adolescents, under the age of 18, who underwent OTC for fertility preservation. The incidence of POI was evaluated in 60 girls who had OTC performed after age 12 and who were still alive at the time of study. A more detailed study was performed in a subgroup of 32 girls who were under the age of 12, without menarche, at the time of OTC and who were older than 14 years at the time of study. In this subgroup, the association between the diagnosis and received treatment and the requirement for medical puberty induction was examined.
Materials and Methods

Practical measures for performing OTC
A specialist in fertility preservation counselled all of the girls and their parents prior to the OTC procedure and obtained written informed consent. The procedure was performed if the risk of infertility later in life was estimated to be high (>50% risk) due to planned treatment with autologous or allogeneic SCT, high dose alkylating agents, high dose irradiation or disease with a known risk of POI (e.g. galactosaemia or Turner syndrome) and if there were no contraindications against the operative procedure.
The OCT procedure and counselling was performed according to the guidelines for fertility preservation of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) (see specification of the guidelines in Materials and Methods) and have not changed over time.
Information on chemotherapy given was retrieved for the subgroup of 32 patients who were prepubertal at time of OTC and post-pubertal at the time of study. It was not possible to obtain the same detailed information for the other 106 patients, who are still alive.
All girls had OTC performed by laparoscopic oophorectomy. In most cases, a right-sided laparoscopic unilateral salpingo-oophorectomy was performed. Young children younger than 2 years had a mini-laparatomy performed and one whole ovary was removed.
Definition of POI
POI is a defect of the ovaries with premature depletion of ovarian follicles. If the onset is prepubertal, it is characterized by absent menarche (primary amenorrhea) and pubertal development. If the onset is post-pubertal, it is characterized by disappearance of menstrual cycles (secondary amenorrhea) and postmenopausal symptoms. The patients are infertile. Biochemically, POI is characterized by high levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) and low levels of oestrogens and inhibins. The patients in our study were defined to have POI if the FSH levels were >20 IU/l at 12 years and above and no signs of puberty development or menarche.
Patients
All Danish girls, younger than 18 years who had OTC performed from 1 March 2000 to 1 August 2015, were included in this study (n = 176). An overview of the girls' diagnoses and mean age at OTC as well as the number of deceased is presented. Two subgroups of patients were further analysed, as outlined below.
In one subgroup, the incidence of POI was evaluated. The subgroup consisted of 60 girls who had OTC performed after the age of 12 and who were still alive at time of study. These 60 girls had either entered puberty or were about to enter puberty at time of OTC. The incidence of POI was evaluated from their patient records, medicine prescriptions of hormone replacement therapy (HRT) and, in some cases, by a telephone interview.
In the second subgroup, the association between the received treatment and the requirement for medical puberty induction was examined. The subgroup consisted of 32 girls who were younger than 12 years at time of OTC without menarche and who were older than 14 years at study. The upper age limit of 14 years for this subgroup was chosen because the vast majority of girls in the background population have started or even finished puberty at this age (USA. 12.5 years, Canada: 12.7, Denmark: 13.5 (Olesen et al., 2000; Anderson et al., 2003; Al-Sahab et al., 2010) ). The subgroup was analysed using patient records. The cumulative doses of chemotherapy or radiotherapy, whether SCT was performed, and status of their puberty development were obtained from the patient records. Furthermore, the hormone levels of FSH, LH and oestradiol obtained at time of OTC to make sure the girl was prepubertal and again at time of either spontaneous menarche or at start of induced puberty were retrieved from laboratory data sheets. Additionally, we registered whether puberty had been induced by exogenous oestradiol therapy. The patient records did not contain sufficient information (Tanner stage) as to when and how patients proceeded through puberty.
The Danish programme for cryopreservation
The programme started in 1999. The counselling of the girl and her parents by a specialist and the harvest of the ovarian tissue was performed at one of three hospitals in Denmark and one hospital in southern Sweden, which also refers patients to our programme.
The preparation and storage of the ovarian tissue is centralized to one centre in Denmark, as described by Rosendahl et al. (2011) . If the tissue is excised at the hospital where the laboratory is located, it is transported in a 37°C culture medium. If the tissue is excised at another hospital, it will be transported in cooled culture medium and placed on crushed ice. The tissue preparation can then be performed up to 5 hours after the excision (Schmidt et al., 2003; Rosendahl et al., 2008) .
Recommendations on fertility preservation for girls and young women with childhood cancer
The guidelines of the NOPHO are outlined below:
(i) All girls should be examined regarding pubertal development (Tanner stage and menstrual history) at diagnosis. (ii) In case of a high risk of infertility, a specialist assigned for this purpose should inform the patient and her parents of the possibilities for fertility preservation. (iii) After treatment, if the girl has received alkylating agents or abdominal irradiation, she should, after sexual maturation, be offered counselling and evaluation by a gynaecologist or a fertility specialist. (iv) Girls who are menstruating and mature enough to give informed consent should be offered ovarian stimulation and cryopreservation of oocytes. If this is offered, the responsible oncologist has to make sure there are no contraindications, such as bleeding disorders, or too long of a delay before cancer therapy. (v) All girls, regardless of pubertal development, with a high risk of future infertility due to the oncological treatment should be offered OTC. (vi) The patients who are eligible for OTC are patients who are facing treatment such as allogeneic/autologous SCT and, RT with an ovary in the field, as well as girls who will undergo ovariectomy for any reason.
Treatment of the subgroup
For all of the 32 girls in the analysed subgroup, we registered the cumulative doses of gonadotoxic chemotherapy and radiotherapy. Of the 32 girls, 31 received alkylating agents, e.g. ifosfamide, cyclophosphamide, treosulfan, busulfan and melphalan. The 32 girls were divided into four treatment groups according to the potential gonadotoxicity of the treatment they had received.
Group 1 included 12 girls who had been treated with alkylating agents and who had received TBI (2-16 Gy) prior to SCT or who had received radiotherapy to the craniospinal axis (CSA), abdominal or pelvic region.
Group 2 included 13 girls who had autologous (1 girl) or allogeneic (12 girls) SCT. Eleven of the girls had received conditioning regimen, which included high dose alkylating agents prior to SCT. The remaining two girls had received lower doses before SCT: one received 4 g/m 2 ifosfamide, 3.6 g/m 2 cyclophosphamide and 6 g/m 2 treosulfan and the other had received 6 g/m 2 cyclophosphamide.
Group 3 included six girls who had received cumulative doses of alkylating agents, such as ifosfamide median 62 g/m 2 (37-78) and/or cyclophosphamide median 7 g/m 2 (1.5-21).
Group 4 (the non-treated group) included one girl who had not received any chemotherapy or radiotherapy, but had an ovary cryopreserved due to a high risk of POI related to her genetic disease (galactosaemia).
Hormone measurements
The FSH, LH and oestradiol levels were measured at the local hospitals using the standard assays in use at their local departments of Clinical Biochemistry. Measuring Anti-Müllerian hormone has only recently become routine in Denmark, and thus this analysis was not performed for the majority of the patients in our cohort.
Statistics
The FSH values have been used to compare patient groups 1-3. A q-plot was performed to see if the values were normally distributed. The values were normally distributed and therefore the data from the three groups were compared by one-way ANOVA and Tukey's multiple comparisons test. P < 0.05 was considered statistically significant. The q-plots were performed in RStudio software (Affero General Public License) for Macintosh, version 0.98.501 and one-way ANOVA and Tukey's multiple comparisons test were performed using Prism (GraphPad) software for Macintosh, version 6.0 h (trial).
Ethical approval
The Ethical Committee of Copenhagen and Frederiksberg approved the project (H-2-2011-044). Data were collected from patient medical records, and the collection and storage of data has been approved by the Ministry of Health (J.no. 30-1372) and by the Danish Data Protection Agency.
Results
General facts on the Danish cohort of girls under the age of 18
The mean age at OTC was 11 years and 3 months (11.3 years) (range of 0.6-17.11) (n = 176). A total of 38 patients had died. The most prevalent diagnoses for OTC were malignant tumours (N = 67) and malignant haematological diseases (N = 42), which represent twothirds of all the patients. Detailed diagnoses, mean age, age range and number of patients who had died are shown in Table I Approximately one-third of the girls in the cohort were 15-18 years old at the time of OTC. The age distribution and the average number of ovarian tissue pieces frozen at the time of OTC are illustrated in Fig. 1 . At time of study, most of the girls in the cohort were 15-25 years old.
General facts of POI development in the girls over 12 years at OTC and still alive at time of study
The incidence of POI was evaluated among the 60 girls who had OTC performed after 12 years of age and who were still alive. The mean age of these girls at the time of OTC was 15.10 years and at study, 21.10 years. Of the 60 girls, 26 (43%) received HRT. The mean age of these 26 girls was 15.11 years at OTC and 22.9 years at the time of the study. There were also six who received oral contraception (OC) and they had taken it continuously since their chemotherapy treatment. There were 27 girls (45%) had regular natural menstrual cycles. Their mean age was 15.9 years at OTC and 21.2 years at the time of study. It was not possible to obtain information on the last girl. In Table II , the diagnosis of the 60 girls who developed POI or not can be seen. Three women have been able to conceive and two of them have given birth to a healthy child and one had an induced abortion. For patients taking OC, we are unable to assess whether they developed POI or not. Most of the young women who have developed POI had been diagnosed with different haematological malignant diseases, but also sarcomas, non-Hodgkin lymphomas, Turner syndrome and other diseases. Most of the young women who are still having regular menstrual cycles were diagnosed with Hodgkin lymphoma, sarcomas, Turner mosaicism and other diseases (see Table II ).
Demographics of the subgroup of girls under 12 years at the time of OTC
In the group of girls who were prepubertal at the time of OTC, the mean age at time of OTC was 8.11 years and hormonal status at time of OTC confirmed that the onset of puberty had not started. At time of this study, the mean age of the girls was 17.6 years. Further information on their diagnosis, mean age and age range at time of cryopreservation and of study is specified in Table III. Medical puberty induction was required in 23 of the 32 girls, which was decided by a specialist, because of clinical signs of delayed puberty with no normal puberty progression (Tanner stages) (see Table IV ). The delayed puberty was either caused by hypergonadotropic hypogonadism with high FSH and LH values or because of hypogonadotropic The risk of having a delayed onset of puberty or the risk of developing POI was compared between the four different treatment groups. Delayed puberty can be defined by the age a girl achieves breast stage 2, which in Denmark should be 13 years of age, and menarche, which should be no later than of 16 years of age. To define if the girls had a delayed onset of puberty or had developed POI, the time of puberty induction or spontaneous menarche was registered. Furthermore, the hormone status (FSH, LH and oestradiol) at time of either spontaneous menarche or induced puberty was registered, as shown in Table IV .
Only two of 12 girls in Group 1 entered puberty spontaneously [Patient no. 3 and 11]. There was no difference in the treatment received or age at time of OTC between the 10 girls with, and the two without, spontaneous puberty.
Eleven of 13 girls in Group 2 received conditioning treatment with either the BuCyMel-(Busulfan-Cyclophosphamide-Melphalan) (N = 6) [Patient no. 13, 14, 17, 19, 20 and 21] or the BuCy-(BusulfanCyclophosphamide) regimen (N = 5) [Patient no. 16, 18, 22, 23 and 25] . All of these 11 girls developed POI and needed medical puberty induction. The other two girls in this group entered puberty spontaneously [Patient no. 15 and 24] . The age of these two girls at OTC did not differ from the rest of the group, but they received lower doses of alkylating agents prior to SCT. One girl was treated with 4 g/m 2 ifosfa- Among the remaining nine girls, who all developed puberty spontaneously, the hormone status at time of menarche was available in five of them, with a mean FSH value of 6.7 IU/l (range 2. 4-16.6) . FSH values at time of medical puberty induction or spontaneous menarche were compared between the three groups, who received gonadotoxic treatment (Fig. 2) . Group 3 consisted of six girls. Five of them developed spontaneous puberty. Two of these girls had FSH values available of 3.6 and 2.4 U/l at menarche [Patient no. 26 and 27], but three had no registered FSH values .
Statistical calculations were performed on the girls' FSH values. An ANOVA analysis was performed on the three groups, which were not significantly different (P = 0.051). Tukey's multiple comparisons test were performed between the groups. The FSH value was significantly higher (P < 0.05) in Group 1 than in Group 3, but the FSH-values were not significantly different between Groups 1 and 2 (P = 0.366) and between Groups 2 and 3 (P = 0.2168) (see Fig. 2 ). These results suggest a difference between the three groups FSH-values. If the sample size of Group 3 had been larger or the three unknown FSH-values had been known, the ANOVA and P-value between Group 2 and 3 could have been significantly different. And the results would be in accordance with the mean age at menarche in the groups, which was 14.0, 14.3, 12.1 years in Group 1, 2, 3, respectively.
Discussion
This study describes the largest cohort of girls younger than 18 years who until now had OTC performed prior to gonadotoxic cancer treatment. The predominant diagnoses indicating OTC were Ewing sarcoma, ALL and Hodgkin lymphoma, comprising a total of 38%. The study demonstrated that girls who received TBI (i.e. Group 1) failed to undergo spontaneous puberty in more than 80% of the cases. The two girls who developed spontaneous puberty did not differ in either age at the time of OTC or in the treatment they received when compared to those who failed to enter puberty spontaneously. All girls who received conditioning treatment with alkylating agents (i.e. Group 2) prior to SCT, subsequently developed POI and needed medical induction of puberty. Among girls in Group 3 who received lower doses of alkylating agents, only one girl needed puberty induction. She appeared similar to the girls who developed spontaneous puberty.
These results confirm that a potential gonadotoxic treatment is associated with a high risk of developing POI. However, predicting which girls will develop POI is difficult in some groups of patients, while those who receive conditioning treatment for SCT and/or irradiation have a considerable risk of subsequent ovarian failure.
The postmenopausal levels of FSH measured in girls who required puberty induction and the cyclical levels in girls who spontaneously underwent puberty confirm the above results. It was found that the measured FSH values differed between the girls in Group 1 and 3. Furthermore, the FSH values seemed to differ between all three groups and are close to significantly different. This shows that although FSH levels are not considered a good predictor of the ovarian reserve, the average levels in the groups still provide an indication of the ovarian function.
Around half of the 60 surviving girls who were older than 12 years at OTC developed POI and half had regular menstrual cycles. The girls who developed POI had mainly suffered from different haematological malignant diseases. The girls who had regular menstrual cycles had a diagnosis of Hodgkin lymphoma in the majority of the cases. We have not had the possibility to evaluate whether girls developing POI had higher doses of cumulative alkylating agents and whether they more often received radiation below the diaphragm compared to the other girls.
This study warrants future follow-up on this cohort to obtain a more accurate estimation on who will develop POI later on in life. The different levels of FSH between the groups may represent an early indication. A long-term follow-up approach is supported by Larsen et al. (2003a,b) who found that childhood cancer survivors with continued ovarian activity and normal basal FSH had ovarian volume and antral follicle count significantly lower than controls, suggesting that survivors with regular menstrual cycles had an impaired ovarian potential. A 10-year follow-up on the same cohort showed that 15% had lost ovarian function, but only 6% was caused by POI. More than 50% of the survivors had succeeded in giving birth, but it was also found that the survivors treated with ovarian irradiation had a diminished ovarian reserve and experienced difficulties in conceiving (Nielsen et al., 2013) . Thomas-Teinturier et al. (2015) found that survivors who received procarbazine and higher cumulative doses of alkylating agents prior to SCT had a reduced ovarian reserve. The same group found that childhood cancer survivors treated with alkylating agents (particularly after the onset of puberty) were at a higher risk of POI and that the risk was increased with even low doses of radiation to the ovaries (ThomasTeinturier et al., 2013) confirming earlier studies (Chiarelli et al., 1999; Sklar et al., 2006; Green et al., 2009) . In a cohort study by Bruin et al. (2008) , the incidence of POI was examined 10 years after treatment. It was found that the risk of developing POI was 64% after high doses and 15% after low doses of cumulative procarbazine. The study also confirmed that the women, who were older at time of treatment, experienced POI earlier than women who were younger when treated. Radiation with ovaries in the field also represents a high risk of developing POI and it is well known that sterilizing doses decrease towards menopause (Wallace et al., 2005b) . Collectively, these data enforce that long-term follow-up of childhood cancer survivors focussing on fertility and ovarian function is important.
In cases of POI, the use of frozen/thawed ovarian tissue for puberty induction or restoration of hormonal production as an alternative to administration of HRT can be an option. It could be more physiological and more attractive for a patient to use her own ovarian tissue, provided that there is no risk of tumour cell contamination by transplantation. The pool of ovarian follicles is relatively large in the young years and a fraction of the stored tissue could be used for natural puberty induction (e.g. two pieces of 5 × 5 mm). As Fig. 1 illustrates, the average amount of tissues cryostored in patients younger than 3 years is 10 pieces. To transplant two pieces of ovarian tissue will not jeopardize the patients fertility potential later on in life, because the cryostored ovarian pieces contains a higher follicle density in younger patients than in older patients. Therefore, the chances for conceiving per transplanted frozen-thawed ovarian piece are most likely to be higher in patients who had ovarian tissue cryostored younger in life than those who were older at the time of OTC. Furthermore, a patient who has puberty induced by transplanted ovarian tissue will still, with her remaining 80% (8 out of 10 pieces remaining, if she was <3 years at time of OTC) of ovarian tissue, have a far greater number of follicles available than in ovaries of women in their mid-twenties to mid-thirties. However, it can also be argued that, for now, the ovarian tissue should only be used for fertility since a valid treatment for puberty induction is available.
A great concern when evaluating the OTC procedure is the risk of malignant cell contamination in the grafted tissue. A study of all the women in our cohort who had ovarian tissue transplanted did not show an increased risk of relapse compared to the women in the cohort who did not have ovarian tissue transplantation (Jensen et al., 2015) . Three patients with grafted tissue had a relapse. One of these patients was the young girl with Ewing sarcoma (see Table III ). All three relapses seemed to be unrelated to the grafted tissue (Rosendahl et al., 2011; Ernst et al., 2013a,b; Yding Andersen et al., 2014) . However, no patients with a former leukemic diagnosis has had ovarian tissue transplanted in Denmark and the safety of the procedure, irrespective of diagnosis, still requires intensive follow-up (Rauff et al., 2016) .
In conclusion, this study supports the use of OTC for fertility preservation in selected young girls. Overall, OTC was warranted in our cohort since 23 out of the subgroup of 32 young patients actually failed to enter puberty spontaneously. We also confirm that there is an association between the treatment received and the risk of developing POI just after end of treatment, although it is not always possible to predict which girls will or will not develop POI. Further, some girls who enter puberty spontaneously may develop POI and may benefit from their frozen tissue later on. However, future long-term follow-up studies are needed.
